Added to YB: 2026-09-14
Pitch date: 2026-09-11
LXRX [neutral]
Lexicon Pharmaceuticals, Inc.
Author Info
No bio for this author
Company Info
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.
Market Cap
$956.7M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-15.83
P/E
-13.54
EV/Sales
19.90
Sector
Pharmaceuticals
Category
special_situation
Biotech Conference coverage Day 3 Session 2 - Lexicon Pharmaceuticals, Inc.
LXRX (quick overview): Lexicon at $2.15 offers a potentially asymmetric setup around sotagliflozin and two binary catalysts. The fully enrolled 500-plus-patient SONATA Phase 3 HCM readout is expected in Q1 2027, with a positive KCCQ result plus supportive NYHA, echocardiographic and safety data potentially supporting an HCM commercial or partnering story; Lexicon expects to resubmit sotagliflozin for type 1 diabetes in Q4 2026. Both programs retain substantial clinical and regulatory risk.
Read full article (2 min)